• 70% of those with epilepsy could live seizure-free lives if properly diagnosed, treated
• Machine-learning algorithms using EEG signals have potential to accurately predict epileptic seizures, allowing patient to take preventive measures
• NeuroCap provides cost-effective solution that is disrupting EEG market

Brain Scientific (OTCQB: BRSF) is modernizing brain diagnostics with cutting-edge technology that bridges the widening gap in access to quality care. The use of artificial intelligence (“AI”) and machine learning (“ML”) is at the forefront of improving epileptic patients’ access to neurological care.

According to the World Health Organization (“WHO”), 50 million people worldwide have epilepsy (https://ibn.fm/NUPCJ). Approximately 70% of those people could live seizure-free lives if properly diagnosed and treated. Seizures are controllable. Through a pilot program, WHO discovered that by merely training primary health-care providers to diagnose and treat epilepsy, more people would have access to the treatment they need.

However, with conventional methods the necessary diagnostic equipment is cumbersome, complicated, and expensive; it also requires a trained technician to administer the tests. A more portable, simple-to-administer test is needed to reach the majority worldwide.

In the United States alone, an estimated 2.3 million adults and more than 450,000 children and adolescents live with epilepsy, with an estimated 150,000 people diagnosed each year (https://ibn.fm/bbcbW). Tragically, access to neurological care is decreasing as the need grows. In 2017, 20 states were considered neurology deserts, meaning they had less than 10 neurologists per 10,000 patients (https://ibn.fm/gnbtU).

A 2019 Advisory Board brief, titled “Navigating the Neurologist Shortage,” reported that the situation was not improving (https://ibn.fm/rP1Nc). “Providers across the country currently struggle to hire neurologists—and the problem shows no sign of abating. Estimates show that demand for neurologists in 2025 will exceed supply by 19%,” the report observed. This makes the wait for essential diagnosis and treatment long — and sometimes dangerous.

The solution may well be BRSF’s neuro-tech ecosystem. This approach consists of the disposable NeuroCap(TM) and a portable wireless NeuroEEG(TM) amplifier. These products provide rural hospitals with easy access to EEG tests.

Machine learning has improved EEG analysis and solved several challenges. Brain Scientific is working on incorporating AI and machine learning processes into the analysis, which will be able to free neurologists from the manual, tedious, and time-consuming portions of their jobs, thereby allowing them to help more patients.

According “Machine Learning for Predicting Epileptic Seizures Using EEG Signals,” which was published in February 2020, when an epileptic seizure is predicted in advance it is possible to take preventative interventions (https://ibn.fm/GXlG2). Machine learning algorithms using EEG signals have the potential to accurately predict epileptic seizures. This state-of-the-art hope for epilepsy still has problems, “cost-effective and efficient hardware implementation remains the bottleneck.”

Brain Scientific is working to disrupt the expensive EEG market. The NeuroCap and NeuroEEG are both approved by the FDA and provide economic and disposable substitutes. Trained technicians are not required to administer the tests, and a neurologist does not have to be on-site to run the analysis. A telemedicine physician can read the results in real time, eliminating long waits, high costs and the risks of exposure to communicable diseases such as COVID.

Brain Scientific is working to make neurological care accessible for all who need it.

For more information, visit the company’s website at www.BrainScientific.com.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

• COVID-19 cases projected to continue to increase in coming weeks, months
• UMEBSNI is trusted supplier of FDA-approved COVID-19 rapid antigen test kits
• United Medical offers additional comprehensive programs for COVID-19 testing

Even as COVID-19 vaccines are finally being approved and distributed, the latest forecast from the Centers for Disease Control and Prevention (“CDC”) predicts that an up to 2 million new COVID-19 cases will likely be reported in the week ending Jan. 16, 2021 (https://ibn.fm/0cNyq). The global pandemic is not yet over, and United Medical Equipment Business Solutions Network Inc. (“UMEBSNI”) continues to move quickly to address the unique testing needs created by the ongoing virus.

As part of its efforts to provide essential services during the epidemic, UMEBSNI is a trusted supplier of FDA-approved COVID-19 rapid antigen test kits (https://ibn.fm/hZ43R). The COVID-19 IgG/IgM Rapid Test Cassette offered by United Medical detects coronavirus antibodies that appear in the bloodstream of individuals infected with the virus within 10 minutes. The test can also indicate whether a person has protection against the coronavirus.

Other features of the test include the following:

• FDA Emergency Use Authorization (“EUA”)
• Small sample sizes; works with whole blood, plasma and serum samples
• Shelf life of up to 24 months from date of manufacture
• Stored at room temperature or refrigerated (2 to 30°C)
• Available in quantities of 25

The kits are for medical professional use only and are approved for use in CLIA moderate- or high-complexity settings. In addition, verification of use case prior to shipping is mandatory.

The IgG/IgM rapid test kits are only the beginning of UMEBSNI’s commitment to offering comprehensive programs for COVID-19 testing. Other services provided by the company include pre-shift temperature checks, medical-grade face masks, hand-sanitizer stations, medical-grade nitrile gloves and face shields.

Finally, the company also offers a unique mobile solution. UMEBSNI mobile testing specialists and experienced medical staff members are available to provide onsite COVID-19 Rapid Testing and solutions to implement employee safety. Mobile units and medical staff are on call and are capable of nationwide deployment for extended periods of time.

United Medical Equipment Business Solutions Network is a provider of reliable resources and solutions to fit the ever-changing needs of an aging population that includes seniors and veterans, as well as those impacted by the COVID-19 pandemic. Uniquely poised to offer health care across the continuum of care, United Medical Equipment has solutions that help providers work more proficiently, health-care systems work smarter and patients live healthier lives.

The company aims to provide the information, technology and proper equipment needed to maintain safety and health among seniors, veterans, health-care workers and other patients.

For more information, visit the company’s website at www.UnitedMedSolutions.com.

NOTE TO INVESTORS: The latest news and updates relating to United Medical Equipment are available in the company’s newsroom at https://ibn.fm/UnitedMed

• U.S. taking actionable steps toward acceptance of psilocybin
• States, individual cities have decriminalized, made use and possession of psilocybin low law-enforcement priority
• More psilocybin research being done focused on health, well-being of Americans facing a mental health crisis on epic levels

Cybin (NEO: CYBN) is a life science company focused on the pharmaceutical development of psychedelic products. The company’s subsidiary Serenity Life Sciences is focused on the research and development of psilocybin-based medications. Psilocybin, referred to by the media as magic mushrooms, has had its share of bad press. The stigma of this substance has halted R&D in America in the past, but that is beginning to change. Under the Controlled Substances Act, psilocybin is included with heroin and LSD as a Schedule I drug. According to the National Drug Intelligence Center, psilocybin serves no legitimate medical purpose in the United States (https://ibn.fm/Z23k3). This view has come under criticism as recent studies surrounding the substance show otherwise. The public’s opinion, state guidelines and pharmaceutical development of psychedelic products are moving towards growing acceptance and legalization. Oregon became the first state to legalize the use of psilocybin for therapeutic use when voters passed Measure 109 on Nov. 3, 2020 (https://ibn.fm/TKCuc), the latest in several steps the country hs been taking toward psilocybin acceptance. In 2005 the Court of Appeals in New Mexico overturned a felony drug trafficking conviction by citing that growing hallucinogenic mushrooms isn’t prohibited under the drug trafficking law’s definition of “manufacture” (https://ibn.fm/yRUSw), marking one of the first indications of what would be a slow-changing tide. Fifteen years later, New Jersey amended a marijuana decriminalization bill to include a lesser punishment for possession of psilocybin from a third-degree felony to a disorderly persons offense (https://ibn.fm/dmb3p). In addition, where states are not decriminalizing psilocybin, individual cities are. Denver was the first U.S. city to decriminalize psilocybin mushrooms. Ordinance 301 was passed with a 50.56% majority in May 2019 (https://ibn.fm/pX7ii). This ordinance keeps the city from prosecuting or arresting adults in possession of or even growing the mushrooms. Other cities across the country have followed suit. Oakland, California, passed a law the following month banning law enforcement from investigating and prosecuting individuals using or possessing drugs sourced from plants, cacti and mushrooms that contain psilocybin (https://ibn.fm/nEBhR). The third city was also in California. Santa Cruz’s City Council voted unanimously in January 2020 to make the investigation and arrest for adult possession, use or cultivation a low-priority infraction (https://ibn.fm/YlVE9). In another unanimous vote in September 2020, Ann Arbor, Michigan’s City Council voted in favor of declaring the investigating and arrest of anyone for planting, cultivating, purchasing, transporting, distributing, engaging in practices with or possessing psilocybin the city’s lowest law enforcement priority (https://ibn.fm/pooRa). All four cities citied indigenous cultural reasons as well as research around the use of psychedelics in the treatment of mental health and as a viable option combating the opioid crisis. More movement is being seen in the decriminalization and push for research across the United States.

• Alexandria Ocasio-Cortez filed legislation for researchers to more easily study the benefits of psychedelic drugs (https://ibn.fm/vDEHF)
• Jeff Shipply filled a bill in the name of personal freedom to decriminalize psilocybin in Iowa
• Initiative 81, voted on by D.C. residents and awaiting review by Congress, makes the possession and use of certain psychedelic plants low priority for the police (https://ibn.fm/yT730)

Criminalization and the stigmas attached have made it difficult for researchers to explore the medical benefits of psilocybin and other psychedelics. As more states accept the cultural and medical benefits of these substances, more research can be done, which could ultimately lead to increased health and well-being of Americans who are facing a mental health crisis on epic levels. With more than 17 million people in the Unted States experiencing at least one major depressive episode (https://ibn.fm/0Wxky), it is past time for new treatment alternatives. Cybin is at the forefront of companies conducting clinical trials for potential new treatment options and is developing innovative approaches to bring new psychedelic-based therapies to patients in need. For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

• UUUU to receive minimum of 2,500 tons of natural monazite ore, one of highest-grade REE minerals in world
• Company to produce raw materials needed for clean energy, advanced technologies while also creating green jobs in economically underserved area
• Energy Fuels will be first U.S. company in years to produce marketable mixed REE concentrate on commercial scale

Energy Fuels (NYSE American: UUUU) (TSX: EFR), a diversified uranium miner, has finalized a three-year agreement with the Chemours Company (NYSE: CC) to obtain natural monazite ore, one of the highest-grade rare earth element (“REE”) minerals in the world (https://ibn.fm/Rp4YN). The agreement calls for Energy Fuels to receive a minimum of 2,500 tons per year and represents a significant step in UUUU’s commitment to be a leader in re-establishing a fully integrated U.S. REE supply chain.

“With our announcement . . .  Southeast Utah is fast becoming America’s clean energy and critical minerals hub,” Energy Fuels president and CEO Mark S. Chalmers stated. “Our goal is to domestically produce the raw materials needed for clean energy and advanced technologies, while creating green jobs in an economically challenged part of the country.

“Currently, the U.S. imports nearly all of our rare earth, uranium and vanadium requirements, despite having ample supplies here in the U.S.,” Chalmers continued. “Importantly, in the United States we are highly regulated and operate to the highest standards, which means we produce these minerals more responsibly than many of the countries from which we currently import. Our agreement with Chemours may be the beginning of a real success story, not only for Energy Fuels, but also for local communities, Native Americans, conservation groups, the State of Utah, and the U.S. as a whole.”

Based on the announcement, Energy Fuels intends to start process the monazite it receives from Chemours beginning the first quarter of 2021. The process will take place at UUUU’s wholly owned White Mesa Mill, which is located in Utah. The company will recover the uranium that results from that process and produce a marketable mixed REE carbonate, an essential step toward re-establishing a fully independent U.S. REE supply chain.

Once Energy Fuels successfully begins this process, UUUU will be the first company in the United States in years to produce a marketable mixed REE concentrate ready for separation on a commercial scale. Based on its estimates, UUUU plans to be able to provide almost 10% of total current U.S. REE demand. REEs are used in a wide variety of clean energy and advanced technologies, including wind turbines, electric vehicles, cell phones, computers, flat-panel displays, advanced optics, catalysts, medicine and national defense applications.

Energy Fuels’ mixed REE carbonate production from monazite ore should use only a  small amount of its White Mesa Mill’s ore-production capacity and produce almost no waste. Initially, UUUU plans on obtaining the 2,500 tons of monazite sands from Chemours, as outlined in the contract, but the company will work to increase monazite ore supply, hopefully reaching approximately 15,000 tons of monazite ore per year. The White Mesa Mill is licensed and designed to process 2,000 tons of ore daily, or 720,000 tons of ore per year, so the anticipated production of monazite sands represents an estimated 2% of its throughput capacity. If successful at reaching those numbers, Energy Fuels projects its White Mesa Mill will be able to produce approximately 50% of U.S. REE demand in a mixed REE carbonate.

For more information, visit the company’s website at www.EnergyFuels.com.

NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU

• Demand for food increasing as world population swells; pesticides paramount to maintain supply
• Countries banning pesticides deemed hazardous, but alternatives are lacking
• MustGrow is solution provider for global food supply with its natural biological crop protection for high-value crops

As the world population is increasing at an accelerated pace, a stable food supply is becoming critical to ensure food availability across the world. MustGrow (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) is playing a key role in providing biotechnology that secures both steady and high-quality crop supply.

To ensure a consistent flow of produce, crops need protection. For that, producers have been using various synthetic pesticides, which have become irreplaceable in creating a stable and abundant food supply for the global population. Indispensable for controlling weeds, pests and plant pathogens that threaten crops, synthetic pesticides contribute to higher yields and improved quality.

Still, not all of pesticides are created equal; some have even been deemed hazardous by the World Health Organization (“WHO”). Some pesticides on that hazardous list are still being used around the world, including in the United States. A recent article cites that around 150 agricultural pesticides considered hazardous to human health by WHO were used in the United States within the last few years (https://ibn.fm/wVmJt).

Although using potentially risky compounds has been an accepted part of the global food industry, the pressure to move away from that is growing. Both industry and governments are increasingly recognizing the importance of natural products to secure a quality food supply for the world while keeping health and safety in mind.

Although some jurisdictions are more advanced in scrutinizing the use of chemical pesticides in human consumption at present — resulting in some of those substances being banned — with globally integrated food supply chains, the world will likely see the convergence of these regulations on the international scale. As this happens, natural alternatives to chemical pesticides will become paramount to ensure a steady stream of crops while also adhering to strict health and safety standards (https://ibn.fm/3kU0S).

As bans on certain chemical pesticides continue to spread, natural alternatives are needed to fill this gap and secure the global food supply. To transition effectively away from chemical pesticides, new “biological” products need to have not only a safer and more eco-conscious profile but comparable efficacy and pricing as well. This is where MustGrow steps in.

As an agriculture biotech company committed to creating natural biological crop protection for high-value crops, MustGrow positions itself as a critical part of the food ecosystem of the future. The company has developed EPA-approved biotechnology that uses the mustard seed’s natural defense mechanism to protect plants from pests and diseases, offering a natural solution as an increasing number of markets seek natural alternatives for chemical pesticides.

Focused on developing breakthroughs in agriculture to enable farmers to use natural, safe and efficient products, MustGrow is a part of the solution to the global food supply problem with its unique, natural and organic product. As the market gap widens, MustGrow’s solution is showing comparable efficacy, consistency and potentially price compared to traditional synthetic chemicals, opening a global opportunity for the pioneering company to leverage the rising demand and help maintain both stable and high-quality food supply.

For more information, visit the company’s website at www.MustGrow.ca.

NOTE TO INVESTORS: The latest news and updates relating to MGROF are available in the company’s newsroom at https://ibn.fm/MGROF

• Wisp Resort has already covered 9,311 room nights and counting with InsuraGuest Hospitality Liability coverage
• The company’s Hospitality Liability Policy helps reduce properties’ risk and claim ratio, which could potentially lower the premiums for General Liability coverages
• InsuraGuest is disrupting the current insurance market by offering digital insurance solutions across multiple sectors – not just hospitality

Innovative insurtech provider InsuraGuest Technologies (TSX.V: ISGI), through the wholly-owned United States subsidiary, InsuraGuest Risk Purchasing Group, Inc., has announced that its annual contract with Wisp Resorts over the Hospitality Liability Coverage has been renewed (https://ibn.fm/7zEtW). Following the renewal, Wisp Resort, the only four-season ski, golf, and recreational destination resort in the mountains of Western Maryland, will continue to provide InsuraGuest Hospitality Liability Policy coverage to its 168-room resort. To date, Wisp has covered 9,311 room nights and counting. By harnessing the power of technology, InsuraGuest has changed the way that insurance is delivered to hotels and vacation rentals. The company’s Hospitality Liability coverage was designed to help the property transfer certain risks away from their General Liability insurance by adding a layer of protection for the property should a guest experience a mishap or accident. This way, the policy helps pay for accidental in-room property damage, lost or stolen goods, medical payments, and accidental death and dismemberment. These often have limitations or high deductibles when exposed to the company’s General Liability insurance coverages. Adversely, some of the claims turned in to General Liability are so small yet create a big impact. The more claims that you have, the higher risk you are. If you are considered a high-risk company, your premiums are higher. With InsuraGuest, hotels and vacation rentals now have the ability to help manage their insurance premiums by transferring certain risks onto the Hospitality Liability policies InsuraGuest provides. Hotel operators can even generate revenue using InsuraGuest. Coverage is activated upon a guest checking into an InsuraGuest covered property. The charge is placed on the guest’s folio, or it is bundled into the resort/amenity/urban fees. The hotel keeps 10% of this charge for their own revenue. The contract with Wisp Resorts is one of several partnerships InsuraGuest has made lately to further cement its leading position on the fast-growing insurtech market. With technology touching almost every industry worldwide, the insurance industry has been no exception. Valued at $5.48 billion in 2019, the global insurtech sector is expected to reach $10.14 billion by 2025, with a CAGR of 10.8% during the forecast period of 2019-2025 (https://ibn.fm/udChj). This growth offers multiple opportunities to InsuraGuest, a company committed to harnessing the power of technology to reinvent the insurance industry. With a proprietary software platform that delivers digital insurance to multiple sectors across various industries, the company aims to revolutionize the way insurance is delivered based on the idea that insurance should be bought and not sold. For more information, visit the company’s website at www.InsuraGuest.com. NOTE TO INVESTORS: The latest news and updates relating to ISGI are available in the company’s newsroom at http://ibn.fm/ISGI

• Autonomous Security Robot (ASR) developer Knightscope has deployed its high-tech sentries at institutions including hospitals, universities, Fortune 1000 companies and even on behalf of NBA team the Sacramento Kings
• Knightscope counts law enforcement personnel and private security industry directors among its Reg A+ investors, who now number more than 17,000 people
• The company recently launched a new app through which its friends can help Knightscope identify ideal locations for ASR security products
• Market analysts predict the global ASR market will grow at a CAGR of 7.93 percent through 2025 to $3.59 billion

Autonomous security robot (“ASR”) developer Knightscope is helping to revolutionize the operations of protective patrols used by private industry as well as the police forces employed by governmental institutions. The company’s indoor and outdoor-mobile ASR sentries have been contracted to help safeguard hospitals, university campuses, an NBA team and numerous Fortune 1000 companies. As evidence of the robots’ effectiveness and success, Knightscope’s investors number more than 17,000 now, among whom are law enforcement personnel and private security industry managers. A Public Safety App just launched by Knightscope in December on both the App Store and Google Play aims to help the company expand its clientele by inviting app users to report any location where they think an Autonomous Security Robot (“ASR”) will contribute to public safety. “Record a video, enter some basic information about the location and submit. Knightscope will follow up on each submission directly and present a solution to the appropriate officials,” a news release about the launch states (https://ibn.fm/0FM7A). The indoor and outdoor robots operate with artificial intelligence-enhanced features such as 360-degree eye-level HD streaming video and speakers for live or recorded communication, data collection and recording, obstacle avoidance, facial recognition, license plate identification, thermal fluctuation detection and broadcast signal reception. Mordor Intelligence analysts predict the global ASR market will grow at a CAGR of 7.93 percent through 2025, from $2.27 billion last year to $3.59 billion (https://ibn.fm/U6aNw), adding that “developments, like K5 by Knightscope, Inc., are indicating a potential future scope for security robots. Earlier, these robots had insufficient capabilities; however, with advances in sensor technology and automation capabilities, these robots have been developed to be useful in working applications.” For more information, visit the company’s website at www.Knightscope.com. Visit www.Knightscope.com/invest for a summary of Knightscope as an investment, with a blue Instant Messaging button for direct contact with their CEO. DISCLAIMER: You should read the Offering Circular and risks related to this offering before investing. This Reg A+ offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/Knight

• Gold hit all-time high as investors flock to protect wealth on the fear of inflation, economic turmoil, currency fluctuations
• To leverage strong momentum of gold, investors may benefit from junior mining stocks
• GoldHaven appears to be well positioned to capitalize on rising attractiveness of gold market

Historically, gold played the role of a safe haven asset during economic decline or increased volatility due to heightened uncertainty. The pandemic has been no different as the precious metal hit its all-time high in early August, surpassing $2,075 per ounce. With the expectation that the price of the precious metal will stay strong in 2021, GoldHaven Resources (CSE: GOH) (OTCQB: GHVNF) looks to be well positioned in the space. As a junior mining company focused on identifying and capitalizing on precious metal projects in mineral-rich districts within stable political jurisdictions, GOH may well be able to leverage the robust momentum of the gold market.

In the latest gold price surge, another driving force emerged — government spending at unprecedented levels. To fight the damaging effects of a looming recession, central banks inject cash into the financial system, a mechanism called monetary easing, while governments embark on a spending spree. Since the onset of the pandemic, the government has injected trillions of dollars, leading to public debt hitting an all-time high in the post-World War II years (https://ibn.fm/6pok8).

These factors traditionally lead to inflation, which in turn pushes up the price of gold. Also, monetary easing lowers investor confidence in the currency’s strength, which then increases the demand for gold as a safe haven. The U.S. Dollar Index tracks the value of the US dollar against a basket of major currencies such as the euro, Japanese yen, pound sterling, Canadian dollar, Swedish krona and Swiss franc. After a spike around the onset of the pandemic, the U.S. Dollar Index shows that the currency has been declining steadily for most of 2020 (https://ibn.fm/i3RFB), making gold even more attractive as an investment alternative.

Investors have various options in gold investing, including buying physical gold or stocks of gold mining companies. Physical gold includes gold bullion, coins and jewelry, for which investors usually need to pay for storage and insurance. Alternatively, they can invest in gold mining companies. As a junior mining company, GoldHaven is poised to benefit from the favorable market environment for gold. According to a recent article published by “Forbes,” investing in junior gold miners may be more attractive during the volatile bull market than larger gold miners (https://ibn.fm/rJX3J).

A gold mining company is worth the value of its gold reserves. Larger companies tend to mine a lot of gold, effectively depleting their reserves every year. To replenish those resources, larger mines can either do explorative work to find new deposits or buy another company with a gold ore stock, which is less risky. As gold price surges, junior miners become more likely to get taken over by larger miners, potentially making their stock prices rally. Also, new gold deposits could make a large difference to a junior miner’s value, while for bigger companies, the impact is usually much smaller. These factors all contribute to the attractiveness of junior miners in times of a strong gold market.

As a Canadian junior exploration company led by a seasoned executive team, GoldHaven is poised to thrive in today’s gold-market environment. With mining assets located in stable political jurisdictions such as the Maricunga Gold Belt of Northern Chile, GoldHaven Resources believes it leverages the right people, the right product, and the right time to capitalize on this favorable environment.

For more information, visit the company’s website at www.GoldHavenResources.com.

NOTE TO INVESTORS: The latest news and updates relating to GHVNF are available in the company’s newsroom at http://ibn.fm/GHVNF

• Neuro-oncology drug developer CNS Pharmaceuticals is completing an underwritten public offering of common stock shares and warrants in a bid to fund its upcoming Phase 2 trials for a candidate in fighting glioblastoma brain cancers
• CNS’s Phase 2 trials are scheduled to begin during Q1 of 2021, building on a Phase 1 trial in which 44 percent of patients saw improvement and one patient has survived cancer-free for nearly 15 years
• The company has designed an ambitious, adaptive trial that allows for an interim analysis of data and adjustments for efficiency in bringing the drug candidate, Berubicin, to hoped-for approval as a glioblastoma treatment
• CNS is aiming for FDA approval of an expedited development pathway to obtain maximum efficiency in its timeline
• A recent syndicated broadcast provided CNS with additional publicity, shining a spotlight on its achievements in obtaining FDA approval for Investigational New Drug (“IND”) status

The dawning of a new year is traditionally a time when people embrace the hope of new promise in defeating the disappointments of the past months, and the advent of 2021’s calendar is perhaps more so than ever as a growing number of vaccines against the worldwide COVID-19 pandemic begin to roll out to the public in tiered priority phases. Also just over the new year’s horizon is the launch of Phase 2 testing by neuro-oncology biopharmaceutical company CNS Pharmaceuticals (NASDAQ: CNSP) as CNS advances an ambitious agenda for developing a drug candidate that has shown promise in the fight against glioblastoma, a deadly brain cancer that has no known cure or longevity-building treatment. CNS’s drug candidate Berubicin was the focus of another company’s Phase 1 safety trials nearly 15 years ago. Out of 25 trial participants in the 2006 analysis, 11 of them (44 percent) achieved “statistically significant improvement in clinical benefit” and one of them continued to survive completely cancer-free as of last Feb. 20, when the most recent patient evaluation was conducted. Since glioblastoma patients have a median survival rate of only 14.6 months from the date of the malignancy’s diagnosis, the patient’s response has excited interest in Berubicin’s potential (https://ibn.fm/8wVG3). CNS recently conducted an underwritten public offering of 5 million shares of common stock as well as warrants to purchase up to 2.5 million shares of common stock, selling the stocks and warrants together at a combined public offering price of $2 per share and warrant to fund the upcoming Phase 2 trial as well as other research and development. CNS also granted the underwriter a 45-day option to purchase up to an additional 750,000 shares of common stock and/or 375,000 warrants to cover over-allotments, if any occur. The offering was expected to close on or about Dec. 28 (https://ibn.fm/4j2B5). “Anthracyclines as a class of chemotherapy have been used for over 60 years to treat a variety of cancers. … However, historically, anthracyclines have never been used to treat primary or metastatic brain cancers because scientists could not demonstrate that anthracyclines were able to cross the blood-brain barrier and achieve significant levels of activity in the brain,” CEO John Climaco said during a recent webinar (https://ibn.fm/c1d6K). “Berubicin may change that history because it is the first anthracycline that, based on limited clinical data, appears to cross the blood-brain barrier and achieve drug levels critical for efficacy against central nervous system malignancies.” The U.S. Food and Drug Administration (“FDA”) approved CNS’s Investigational New Drug (“IND”) application for Berubicin shortly before Christmas, and the company’s success in that endeavor was highlighted in a recent broadcast via NetworkNewsAudio (“NNA”) to thousands of syndication points (https://ibn.fm/F8N5C). “Since becoming a public company, our clear focus has been on advancing the clinical development of Berubicin. We will now rapidly move to initiate our Phase 2 trial of Berubicin for adults with GBM and expect to begin enrolling patients in the first quarter of next year,” Climaco stated in a news release about the broadcast. “The Company will transform within the next several months as Berubicin becomes the subject of up to three active clinical trials, which include our randomized, controlled Phase 2 trial in the U.S., and 2 trials planned by our sublicensee WPD in Poland.” The trial’s adaptive, stage-progressive design is intended to allow an interim analysis of the data for efficacy and then to allow an adjustment in patient population if necessary to make the most efficient and rapid use of time. CNS anticipates its trial strategy may potentially grant it an expedited pathway for development with the FDA if it continues to be successful. For more information, visit the company’s website at www.CNSPharma.com NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• Frank D. Heuszel, Sassuan (Sam) Lee are DSS board members; will serve as SHRG directors
• New board members focused on helping SHRG continue to develop products and markets, grow independent sales force, build shareholder value
• DSS owns 37% of the outstanding shares of Sharing Services

Sharing Services Global (OTCQB: SHRG), a diversified holding company specializing in the health and wellness direct-selling industry, has announced two new board members. The new members — Frank D. Heuszel and Sassuan (Sam) Lee — will serve as directors and are Document Security Systems Inc. (“DSS”) board members (https://ibn.fm/TG7h2). DSS owns 37% of the outstanding shares of Sharing Services. “I look forward to being part of the team to help grow Sharing Services and to build upon the success that their team and the other Sharing Services Directors have already achieved. I am excited about helping Sharing Services continue to serve its customers, develop new products and markets, to grow its independent representative network, and to build shareholder value,” said Heuszel, CEO of DSS. Heuszel is a practicing attorney, a certified public accountant, and a certified internal auditor. He has almost 40 years of experience in accounting and finance matters. Mr. Heuszel’s law practice focuses on the regulation and operation of banks, corporate restructures, and mergers and acquisitions. “The success that this company has achieved thus far is amazing, and I hope to bring my expertise and international business experience to the Board and continue to add value,” said Lee, a prominent entrepreneur and finTech executive. Lee has more than 20 years’ experience in the TMET sector, with substantial success in commercializing various blockchain, digital and e-business projects. His vision is to bring wealth inclusion and improve economic inequality in the world by diminishing the boundaries among nations and connecting isolated economies through financial technology and innovation. DSS is a multinational company operating businesses focusing on brand protection technology, blockchain security, direct marketing, healthcare, real estate and securitized digital assets. Document Security Systems is interested in SHRG because its focus on maximizing shareholder value through the acquisition and development of innovative companies, products, and technologies in the direct-selling industry dovetails nicely with DSS’s objectives. Sharing Services Global Corporation is a publicly traded company dedicated to maximizing shareholder value through the acquisition and development of innovative companies, products and technologies in the direct selling sector and other industries. The Sharing Services combined platform currently leverages the capabilities and expertise of various companies that market and sell products direct to the consumer through independent contractors. Sharing Services has two primary divisions: Elevacity(R) Holdings LLC, the parent company of Elevacity U.S. LLC, a health and wellness products company, and Elepreneurs Holdings LLC, the parent company of wholly owned subsidiary Elepreneurs U.S. LLC, a sales and marketing company based on utilization of independent contractor distributors who sell the Elevacity product line. For more information about the company, please visit www.SHRGInc.com, www.Elevacity.com or www.Elepreneur.com. NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG